Condition: Meningioma · Sponsor: University Hospital, Basel, Switzerland
Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor Radionuclide Therapy (PRRT), has proven to be an effective treatment in metastatic intestinal neuroendocrine tumours and is currently used in advanced, recurrent or progressive meningiomas with promising results. In this study, the therapeutic index of a standard and newly developed radiolabelled somatostatin antagonist will be evaluated and compared in PRRT. In a second step, safety and efficacy of the latter will be assessed.
This description comes directly from the study's public registry record.
Damian Wild, Prof. Dr. med. · +41 61 328 6683 · damian.wild@usb.ch
Dominik Cordier, PD Dr. med. · +41 61 55 65 642 · dominik.cordier@usb.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel, Department of Neurosurgery | Basel, Canton of Basel-City, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04997317